Loading...
Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions
A poor prognosis of pancreatic ductal adenocarcinoma (PDAC) associated with chemoresistance has not changed for the past three decades. A multidisciplinary diagnosis followed by surgery and chemo(radiation)therapy is the main treatment approach. However, gemcitabine- and 5-fluorouracil-based therapi...
Na minha lista:
| Udgivet i: | J Hematol Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5793409/ https://ncbi.nlm.nih.gov/pubmed/29386069 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-017-0551-7 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|